Precision radiation spares key areas, may cut prostate cancer treatment side effects
NCT ID NCT05668351
First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The approach spares the urethra, rectum, and pudendal artery to potentially reduce urinary and bowel side effects. About 42 men will receive this treatment and be followed for up to 2 years to compare side effect rates with standard SABR.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.